Cargando…
Sustained Suppression of Gorlin Syndrome-Associated Basal Cell Carcinomas with Vismodegib or Sonidegib: A Case Series
Nevoid basal-cell carcinoma syndrome (Gorlin syndrome) is characterized by numerous cutaneous basal cell carcinomas mediated by mutations in the hedgehog pathway. Vismodegib or sonidegib represent promising treatment options. We identified 10 Gorlin patients who were treated with sonidegib (n = 6) o...
Autores principales: | Wescott, Raquel, Samlowski, Wolfram |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10604938/ https://www.ncbi.nlm.nih.gov/pubmed/37887561 http://dx.doi.org/10.3390/curroncol30100661 |
Ejemplares similares
-
Sonidegib after vismodegib discontinuation in a patient with Gorlin–Goltz syndrome and multiple basal cell carcinomas
por: Piccerillo, Alfredo, et al.
Publicado: (2021) -
Tolerance of sonidegib after intolerance of vismodegib—Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome)
por: Venturi, Federico, et al.
Publicado: (2023) -
A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
por: Odom, Dawn, et al.
Publicado: (2017) -
Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma
por: García Ruiz, Antonio J, et al.
Publicado: (2022) -
Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib
por: Yoon, Jaeyoung, et al.
Publicado: (2017)